• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>NPS Pharmaceuticals

NPS Pharmaceuticals

  1. No Exit: Can the Fed Normalize Rates–And How Will It Impact Stocks?

    We're placing NPS Pharmaceuticals NPSP under review as we digest a number of positive developments over the past 60 days. We plan to significantly raise our fair value estimate. The company refinanced its convertible notes due 2008 with minimal shareholder dilution. This paves the way for NPS to ...

  2. Five Things You Should Know About U.S. Small-Caps

    NPS Pharmaceuticals NPSP raised $50 million Monday through the sale of its Preotact royalty stream to Drug Royalty Corporation. We're maintaining our fair value estimate as we believe the exchange was fair but not favorable to shareholders. The proceeds will satisfy part of a $190 million ...

©2017 Morningstar Advisor. All right reserved.